{"id":1382,"date":"2026-09-04T02:05:00","date_gmt":"2026-09-04T02:05:00","guid":{"rendered":"https:\/\/vistaralabs.ca\/tesamorelin-visceral-fat-human-trials\/"},"modified":"2026-09-04T09:15:09","modified_gmt":"2026-09-04T09:15:09","slug":"tesamorelin-visceral-fat-human-trials","status":"publish","type":"post","link":"https:\/\/vistaralabs.ca\/fr\/tesamorelin-visceral-fat-human-trials\/","title":{"rendered":"Tesamorelin and Visceral Fat: The Trial Record"},"content":{"rendered":"<p><strong>Tesamorelin is an approved medication, which means its evidence is measured in large randomized trials rather than early reports.<\/strong> Two of them, published in <em>AIDS<\/em>, quantify its effect on visceral fat.<\/p>\n<h2>Findings<\/h2>\n<ul class=\"vl-findings\">\n<li>Tesamorelin is an approved medication, tested in large randomized placebo-controlled trials.<\/li>\n<li>In those trials it reduced <strong>visceral fat<\/strong> (the deep belly fat around the organs) by about <strong>18%<\/strong>, versus essentially no change on placebo.<\/li>\n<li>Blood triglycerides also fell substantially.<\/li>\n<li>The effect holds while treatment continues and reverses after stopping.<\/li>\n<\/ul>\n<h2>The 52-week trial (AIDS, 2008)<\/h2>\n<p>HIV patients with central fat accumulation were randomized to tesamorelin 2 mg or placebo daily. Over 52 weeks, visceral adipose tissue fell 18% and triglycerides fell 51 mg\/dl versus baseline (both P&lt;0.001). Total cholesterol also improved, and the treatment was generally well tolerated with glucose parameters not clinically affected. The visceral-fat reduction was sustained during treatment, though it reaccumulated once tesamorelin was stopped.<\/p>\n<h2>The modern-regimen trial (AIDS, 2024)<\/h2>\n<p>Because the original Phase 3 work predated integrase-inhibitor therapy, a newer randomized, double-blind study re-examined tesamorelin in people on those regimens. Over 12 months it produced significant declines in visceral fat (median -25 cm\u00b2 vs +14 on placebo, P=0.001), hepatic fat (-4.2% vs -0.5%, P=0.01), and trunk-to-appendicular fat ratio, with no worsening of glycemic control.<\/p>\n<h2>What tesamorelin is<\/h2>\n<p>Tesamorelin is a stabilized analogue of growth hormone-releasing hormone (GHRH). It prompts the body&#8217;s own pulsatile growth-hormone release rather than supplying growth hormone directly, which is the mechanism behind its effect on visceral fat. Our <a href=\"https:\/\/vistaralabs.ca\/tesamorelin-ghrh-analogue\/\">tesamorelin explainer<\/a> covers the GHRH mechanism, and our <a href=\"https:\/\/vistaralabs.ca\/cjc-1295-ipamorelin-vs-tesamorelin\/\">comparison with CJC-1295 and ipamorelin<\/a> places it among the growth-hormone-axis peptides.<\/p>\n<div class=\"vl-note\">\n<p>Vistara Labs stocks <a href=\"https:\/\/vistaralabs.ca\/tesamorelin-10mg\/\">tesamorelin 10&nbsp;mg<\/a> research vials, shipped from within Canada to every province.<\/p>\n<\/div>\n<h2>Frequently asked questions<\/h2>\n<h3>What did tesamorelin do to visceral fat in trials?<\/h3>\n<p>In a 52-week randomized trial of people with HIV and abdominal fat accumulation, tesamorelin produced a sustained 18% reduction in visceral adipose tissue and a 51 mg\/dl fall in triglycerides versus baseline. A 2024 trial confirmed significant visceral and liver-fat reductions on modern HIV regimens.<\/p>\n<h3>Is tesamorelin an approved medication?<\/h3>\n<p>Yes. Tesamorelin is FDA-approved to treat abdominal fat accumulation in people with HIV, which is why its trial record is unusually complete for a research peptide.<\/p>\n<h3>Does the effect last after stopping?<\/h3>\n<p>In the 52-week study, the reduction in visceral fat was sustained throughout treatment, but visceral fat reaccumulated after tesamorelin was discontinued.<\/p>\n<p class=\"vl-citation\"><em>Sources: Falutz J, et al. Long-term safety and effects of tesamorelin in HIV patients with abdominal fat accumulation. AIDS. 2008;22:1719-1728. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18690162\/\" rel=\"nofollow noopener\" target=\"_blank\">PMID 18690162<\/a>. Russo SC, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38:1758-1765. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38905488\/\" rel=\"nofollow noopener\" target=\"_blank\">PMID 38905488<\/a>.<\/em><\/p>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"FAQPage\", \"mainEntity\": [{\"@type\": \"Question\", \"name\": \"What did tesamorelin do to visceral fat in trials?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"In a 52-week randomized trial of people with HIV and abdominal fat accumulation, tesamorelin produced a sustained 18% reduction in visceral adipose tissue and a 51 mg\/dl fall in triglycerides versus baseline. A 2024 trial confirmed significant visceral and liver-fat reductions on modern HIV regimens.\"}}, {\"@type\": \"Question\", \"name\": \"Is tesamorelin an approved medication?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Yes. Tesamorelin is FDA-approved to treat abdominal fat accumulation in people with HIV, which is why its trial record is unusually complete for a research peptide.\"}}, {\"@type\": \"Question\", \"name\": \"Does the effect last after stopping?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"In the 52-week study, the reduction in visceral fat was sustained throughout treatment, but visceral fat reaccumulated after tesamorelin was discontinued.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Randomized trials of tesamorelin, an approved GHRH analogue, showed an 18% reduction in visceral fat and a 51 mg\/dl drop in triglycerides. The human evidence, plainly stated.<\/p>","protected":false},"author":1,"featured_media":1284,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","_vistara_fr_title":"","_vistara_fr_desc":"","_vl_research_product":1139,"footnotes":""},"categories":[33],"tags":[],"vl_research_area":[41],"class_list":["post-1382","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptide-research"],"_links":{"self":[{"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/posts\/1382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/comments?post=1382"}],"version-history":[{"count":2,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/posts\/1382\/revisions"}],"predecessor-version":[{"id":1453,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/posts\/1382\/revisions\/1453"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/media\/1284"}],"wp:attachment":[{"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/media?parent=1382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/categories?post=1382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/tags?post=1382"},{"taxonomy":"vl_research_area","embeddable":true,"href":"https:\/\/vistaralabs.ca\/fr\/wp-json\/wp\/v2\/vl_research_area?post=1382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}